The evolution of lipid nanoparticles: Paving the way for next-generation nucleic acid medicines
Xuan Lin , Hongguang Xiang , Jiong Wu , Ruixi Liao , Yuhao Li , Bohui Xu , Ying Xu , Yan Shen , Qian Li , Yu Tian
Asian Journal of Pharmaceutical Sciences ›› 2026, Vol. 21 ›› Issue (1) : 101121
Nucleic acid-based therapies have emerged as promising strategies for the regulation of gene expression and the production of therapeutic antigens or proteins for a series of diseases, including cancers, rare diseases, and infectious diseases. However, their clinical application faces challenges. These include high molecular weight, limited cellular uptake, and susceptibility to enzymatic degradation by nucleases in vivo. Both viral and non-viral delivery vectors have been developed as a means of addressing these limitations, including lipid nanoparticles (LNPs), exosomes, polymers, and inorganic nanoparticles. Among these, LNPs have garnered significant attention due to their superior biocompatibility, high delivery efficiency and customizable design potential, as demonstrated by the clinical success of the FDA-approved siRNA drug Onpattro®. The critical role of nucleic acid drug carriers is discussed in this review. It also outlines the major types of carriers under development and examines the advancements and applications in LNP-based systems for nucleic acid delivery. By conducting a review of recent advancements in LNP design, delivery mechanisms, and clinical applications, this article aims to clarify the ways in which LNPs overcome delivery barriers, compare LNPs with other carriers, and identify key trends that can inform the development of next-generation LNP platforms for nucleic acid therapeutics.
Nucleic acid therapeutics / Nucleic acid drugs / Delivery systems / Nucleic acid delivery challenges / Lipid nanoparticle carriers
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
Yamada Y. Nucleic acid drugs-current status, issues, and expectations for exosomes. Cancers (Basel) 2021; 13: 5002. |
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
Hou X, Zaks T, Langer R, |
| [16] |
|
| [17] |
Yan Y, |
| [18] |
Kim H, |
| [19] |
|
| [20] |
|
| [21] |
Adams D, Gonzalez-Duarte A, O’Riordan WD, Yang C-C, Ueda M, Kristen AV, |
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
Della Pelle G, |
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
Wan T, Zhong J, Pan Q, Zhou T, Ping Y, |
| [38] |
|
| [39] |
|
| [40] |
|
| [41] |
|
| [42] |
|
| [43] |
|
| [44] |
|
| [45] |
Shan S, Chen J, Sun Y, Wang Y, Xia B, Tan H, |
| [46] |
|
| [47] |
|
| [48] |
|
| [49] |
|
| [50] |
|
| [51] |
|
| [52] |
|
| [53] |
|
| [54] |
|
| [55] |
|
| [56] |
|
| [57] |
|
| [58] |
|
| [59] |
|
| [60] |
|
| [61] |
Rajagopal P, Duraiswamy S, Sethuraman S, Giridhara Rao J, Krishnan UM. Polymer-coated viral vectors: hybrid nanosystems for gene therapy. J Gene Med 2018; 20: e3011. |
| [62] |
|
| [63] |
|
| [64] |
|
| [65] |
|
| [66] |
|
| [67] |
|
| [68] |
|
| [69] |
|
| [70] |
|
| [71] |
|
| [72] |
|
| [73] |
|
| [74] |
|
| [75] |
|
| [76] |
|
| [77] |
|
| [78] |
|
| [79] |
Arsenijevic Y, Berger A, Udry F, |
| [80] |
|
| [81] |
Locatelli F, Thompson AA, Kwiatkowski JL, Porter JB, Thrasher AJ, Hongeng S, |
| [82] |
|
| [83] |
|
| [84] |
|
| [85] |
|
| [86] |
|
| [87] |
|
| [88] |
|
| [89] |
Kuang G, Lu H, He S, Xiong H, Yu J, Zhang Q, |
| [90] |
|
| [91] |
|
| [92] |
|
| [93] |
|
| [94] |
|
| [95] |
|
| [96] |
|
| [97] |
|
| [98] |
|
| [99] |
|
| [100] |
|
| [101] |
|
| [102] |
|
| [103] |
|
| [104] |
|
| [105] |
|
| [106] |
|
| [107] |
|
| [108] |
|
| [109] |
|
| [110] |
|
| [111] |
|
| [112] |
|
| [113] |
|
| [114] |
|
| [115] |
|
| [116] |
|
| [117] |
|
| [118] |
|
| [119] |
Rajchakit U, |
| [120] |
|
| [121] |
|
| [122] |
|
| [123] |
|
| [124] |
|
| [125] |
|
| [126] |
|
| [127] |
|
| [128] |
|
| [129] |
|
| [130] |
|
| [131] |
|
| [132] |
Mohammadpour R, Dobrovolskaia MA, Cheney DL, Greish KF, |
| [133] |
|
| [134] |
|
| [135] |
|
| [136] |
|
| [137] |
|
| [138] |
|
| [139] |
Maeki M, Uno S, Niwa A, Okada Y, |
| [140] |
|
| [141] |
|
| [142] |
|
| [143] |
Patel S, Ryals RC, Weller KK, Pennesi ME, |
| [144] |
|
| [145] |
|
| [146] |
|
| [147] |
|
| [148] |
|
| [149] |
|
| [150] |
|
| [151] |
|
| [152] |
|
| [153] |
|
| [154] |
|
| [155] |
|
| [156] |
|
| [157] |
|
| [158] |
|
| [159] |
|
| [160] |
|
| [161] |
|
| [162] |
|
| [163] |
|
| [164] |
|
| [165] |
Cheng Q, Wei T, Farbiak L, |
| [166] |
|
| [167] |
|
| [168] |
|
| [169] |
|
| [170] |
|
| [171] |
|
| [172] |
|
| [173] |
|
| [174] |
|
| [175] |
|
| [176] |
|
| [177] |
|
| [178] |
|
| [179] |
|
| [180] |
|
| [181] |
|
| [182] |
|
| [183] |
|
| [184] |
|
| [185] |
|
| [186] |
|
| [187] |
|
| [188] |
Maugeri M, Nawaz M, Papadimitriou A, Angerfors A, Camponeschi A, Na M, |
| [189] |
Sahay G, Querbes W, Alabi C, Eltoukhy A, Sarkar S, Zurenko C, |
| [190] |
|
| [191] |
|
| [192] |
|
| [193] |
Homma K, Miura Y, Kobayashi M, Chintrakulchai W, Toyoda M, Ogi K, |
| [194] |
|
| [195] |
|
| [196] |
|
| [197] |
|
| [198] |
|
| [199] |
|
| [200] |
|
| [201] |
Karikó K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, |
| [202] |
|
| [203] |
|
| [204] |
|
| [205] |
|
| [206] |
|
| [207] |
Parhiz H, Shuvaev VV, Pardi N, Khoshnejad M, Kiseleva RY, Brenner JS, |
| [208] |
|
| [209] |
Maestro S, Weber ND, Zabaleta N, Aldabe R, Gonzalez-Aseguinolaza G. Novel vectors and approaches for gene therapy in liver diseases. JHEP Rep 2021; 3: 100300. |
| [210] |
|
| [211] |
Mahalingam G, |
| [212] |
|
| [213] |
|
| [214] |
|
| [215] |
|
| [216] |
|
| [217] |
|
| [218] |
|
| [219] |
|
| [220] |
|
| [221] |
|
| [222] |
|
| [223] |
|
| [224] |
|
| [225] |
|
| [226] |
|
| [227] |
|
| [228] |
|
| [229] |
|
| [230] |
|
| [231] |
|
| [232] |
|
| [233] |
Zhao G, Xue L, |
| [234] |
Kassab G, Doran K, Mo Y, |
| [235] |
|
| [236] |
Cina C, Majeti B, O’Brien Z, Wang L, |
| [237] |
|
| [238] |
|
| [239] |
Nau R, Sörgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev 2010; 23: 858-83. |
| [240] |
|
| [241] |
|
| [242] |
|
| [243] |
|
| [244] |
|
| [245] |
|
| [246] |
Ogawa K, Kato N, Yoshida M, Hiu T, Matsuo T, Mizukami S, |
| [247] |
|
| [248] |
|
| [249] |
|
| [250] |
|
| [251] |
|
| [252] |
Soroudi S, |
| [253] |
|
| [254] |
|
| [255] |
|
| [256] |
Back PI, Yu M, Modaresahmadi S, Hajimirzaei S, Zhang Q, Islam MR, |
| [257] |
|
| [258] |
|
| [259] |
|
| [260] |
|
| [261] |
|
| [262] |
|
| [263] |
|
| [264] |
|
| [265] |
|
| [266] |
|
| [267] |
|
| [268] |
|
| [269] |
|
| [270] |
|
| [271] |
|
| [272] |
|
| [273] |
|
| [274] |
|
| [275] |
|
| [276] |
Bader J, Brigger F, Leroux J-C. Extracellular vesicles versus lipid nanoparticles for the delivery of nucleic acids. Adv Drug Deliv Rev 2024; 215: 115461. |
| [277] |
|
| [278] |
|
| [279] |
|
| [280] |
|
| [281] |
|
| [282] |
|
| [283] |
|
| [284] |
Simonsen JB. Lipid nanoparticle-based strategies for extrahepatic delivery of nucleic acid therapies - challenges and opportunities. J Control Release 2024; 370: 763-72. |
| [285] |
|
| [286] |
Yamazaki K, Kubara K, Ishii S, Kondo K, Suzuki Y, Miyazaki T, |
| [287] |
|
| [288] |
|
/
| 〈 |
|
〉 |